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lNTRODUCTION
Although mortality from myocardial infarction is
ecreasing in developed countries, the overall burden
rom cardiovascular disease remains enormous, and
orbidity is likely to increase as aging patients survive
onger [1]. Therapies that can offer even partial res-
oration of organ function are likely to be pursued
ith alacrity. There is widespread belief that bone
arrow–derived cells may provide an attractive and
elatively inexpensive alternative or adjunct to the
harmaceutical or surgical management of heart dis-
ase. Interest in the cell therapy of heart disease was
nitially stimulated by evidence that autologous skel-
tal myoblasts could differentiate into striated muscle
n damaged myocardium and improve cardiac func-
ion in animal models [2,3] and patients [4]. These
tudies have led to an ongoing prospective random-
zed trial of autologous human skeletal myoblasts.
nterest increased to enthusiasm when Orlic et al. [5],
sing a murine myocardial infarct model, showed that
he direct intramyocardial injection of lineage-de-
leted c-kit bone marrow cells led to improved he-
odynamic function and the presence of green ﬂuo-
escent protein–marked cardiomyocytes and vascular
tructures in the damaged myocardium. Since then,
umerous animal models have been investigated, and
everal clinical studies, including a prospective ran-
omized trial, have been reported. Although it is per-
aps too early to provide deﬁnitive outcomes, these
aboratory and clinical studies have raised additional,
nd sometimes perplexing, questions.
RECLINICAL MODELS
In most cases, investigators have used transgenic
ouse models with marked hematopoietic cells to
ssess the effect on and fate of the cell population of
nterest. Differences in outcome may, in part, be ex- ilained by wide variations in technique. For example,
different murine models of myocardial infarction
ave been used: the ﬁxed occlusion of a coronary
rtery and an ischemia/reperfusion approach that bet-
er mimics human pathophysiology. The timing and
outes of the administration of the cells (Table 1) also
ary from study to study and may be critical determi-
ants of outcome. Moreover, a variety of cell types
ave been administered and prepared under different
ulture conditions (Table 2).
The observation of engraftment of hematopoietic
ells at sites of ischemic myocardium remains contro-
ersial. Whereas some investigators have observed
igniﬁcant levels of engraftment [5-7], although what
istinguishes directed homing and physiologic en-
raftment from passive adhesion and trapping is not
learly addressed in the literature, others have not
etected signiﬁcant levels of hematopoietic cells in
he injured myocardium [8-10]. Perhaps even more
ontroversial is the issue of the differentiation of he-
atopoietic cells into cardiomyocytes. Several inves-
igators have documented the acquisition of cardio-
yocyte characteristics in hematopoietic cells that
ave lodged at sites of myocardial ischemia [5-7]. This
s consistent with the observation that up to 16% of
ardiomyocytes in male cardiac transplant recipients
f female hearts are derived from recipient male cells,
y using the Y-chromosome as a marker [11]. Also,
ardiomyocytes of male origin have been documented
n females undergoing allotransplantation with male
onor marrow, albeit at lower levels (0.23%) [12].
evertheless, a recent and particularly careful study
ith a murine transgenic experimental myocardial in-
arct model failed to ﬁnd any evidence of transdiffer-
ntiation of hematopoietic stem cells into cardiomy-
cytes [9]. In that study, the marker was the nuclear
ocalized -galactosidase reporter driven by the card-
ac-speciﬁc -myosin heavy-chain gene promoter.
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Bonsequently, detection of transdifferentiated hema-
opoietic cells did not rely on an immunoﬂuorescence
eadout and hence was not subject to the potentially
onfounding feature of autoﬂuorescence that could
ead to a false-positive result. Another study found low
evels of marker-positive (green ﬂuorescent protein–
ositive) cells that did not express cardiac speciﬁc
arkers but retained the CD45 antigen [10].
A possible explanation for the presence of car-
iomyocytes derived from hematopoietic cells is cell
usion. Although the sex-mismatched allotransplant
tudy failed to ﬁnd any evidence of cell fusion be-
ween host cardiomyocytes and donor hematopoi-
tic cells at a frequency of less than 1 in 368,
nother study demonstrated in vitro cell fusion be-
ween mouse bone marrow cells and male embry-
nic stem cells [13]. In an elegant study using the
re/lox recombination technique, Alvarez-Dolado
t al. [14] showed that bone marrow–derived cells
an fuse spontaneously with cardiomyocytes in vivo
t levels of up to 0.9%. Controversies regarding the
requency and origin of the cells lodging in ischemic
yocardium notwithstanding, many studies conﬁrm
mprovement in hemodynamic parameters—espe-
ially left ventricular function—after treatment with
variety of hematopoietic and other cells (including
one marrow stromal cells) in experimental myo-
ardial infarct models [5,8,14,15]. There seems to
e a consensus that improvement in cardiac func-
ion is unlikely to be the result of the relatively low
requency of lodged or engrafted cells. A number of
ossible explanations have been offered, although
able 1. Routes of Administration in Laboratory and Clinical Studies
Intramyocardial (into border zone of infarct or into scar),
direct during CABG or percutaneously
Transendocardial (requires electromechanical mapping
technique) (NOGA)
Intracoronary
Intravenous
Stem cell mobilization by cytokines (G-CSF)
ABG indicates coronary artery bypass grafting; G-CSF, granulo-
cyte colony-stimulating factor.
able 2. Cell Types Administered
Unmanipulated bone marrow cells
Cultured mononuclear bone marrow–derived cells
Adherent bone marrow–derived cells
Bone marrow stromal cells
Peripheral blood–derived mononuclear cells
G-CSF–mobilized peripheral blood cells
CD133-enriched G-CSF–mobilized peripheral blood cells
CD34 bone marrow cells
Lin c-kit Sca 1 cells
Lin c-kit cellsd-CSF indicates granulocyte colony-stimulating factor.
B&MTithout compelling evidence, for the beneﬁcial ef-
ect, and these are listed in Table 3.
LINICAL STUDIES
At least 9 small clinical trials investigating more
han 100 patients receiving bone marrow–derived
ells have been reported and are summarized in Table 4.
everal conclusions emerge from an appraisal of these
tudies. First, acute complication rates seem very low,
lthough the number of subjects in any given study is
mall and long-term follow-up has yet to be reported
or any trial. Second, uncertainty remains regarding
he importance of a host of variables regarding out-
ome. These variables include the route of cell deliv-
ry and the optimum timing after myocardial infarc-
ion for the cells to be delivered. Which cell type and
ell dose give the best results remains unknown. In the
ilot and phase I studies that have been reported to
ate, the measurement of outcome has appropriately
ocused on acute toxicity and changes in global left
entricular function. It remains unknown whether the
eneﬁcial effects observed in some of the trials are
ustained or predict clinically important outcomes,
uch as a reduction in mortality after acute myocardial
nfarction or a lower incidence of severe congestive
ardiomyopathy. These outcomes must await the re-
ults of phase II/III trials and, especially, prospective,
andomized, and (preferably) blinded studies, with
hich the cardiology community is very familiar. Fi-
ally, the time is approaching for groups to develop
ulticenter studies that can address some of these
ritical issues that will better and more rapidly deter-
ine the appropriate role of therapy with bone mar-
ow–derived cells in cardiac regeneration.
ONCLUSION
There are well-established precedents that the in-
estigation of potentially effective therapy need not be
elayed until deﬁnitive mechanisms of action are elu-
idated. For example, embarking on a large study to
ddress the role of unfractionated BM cells would
eem reasonable, despite our lack of knowledge of how
he cells improve cardiac function. Nevertheless,
iven the lack of preclinical data correlating levels of
onor cell engraftment at sites of ischemic myocar-
able 3. Possible Explanations for Improved Cardiac Function after
dministration of Bone Marrow–Derived Cells
Neovascularization
Paracrine effect: cytokine/chemokine release
Extracellular matrix remodeling
Recruitment of endogenous stem cells
Engraftment/differentiation/cell fusion of administered cellsium with myocardial function and the recent report
3
Table 4. Clinical Trial Summary
Study Sample Size Route of Delivery Cell Type Outcome Complications Comment
Hamano 2001 [16] 5 Intramyocardial injection
during CABG
BM mononuclear cells Improved coronary perfusion
in 3 of 5
at 1 y
None CABG confounding factor;
results compared with
30 historical controls
Strauer 2002 [17] 10 Intracoronary via balloon
catheter 7-8 days after
MI
Cultured BM
mononuclear cells
Reduced infarct size,
improved wall motion, and
LVE systolic volume
compared with 10
historical controls at 3 mo
None Comparison with historical
controls
Assmus 2002 [18] 20 Angioplasty and stenting
followed by
intracoronary infusion
3-4 d after MI
BM mononuclear cells
(n  9) versus
peripheral blood
mononuclear cells
cultured for 3 d (n
 11)
Improved global LVEF and
regional wall motion and
reduced end-systolic LV
volume. No difference
between BM and PB cells
None Compared with 11
patients matched for EF,
infarct size, and
localization
Stamm 2003 [19] 6 CABG and
intramyocardial
injection >10 d to <3
months after MI
BM mononuclear cells
positively selected
for AC133 fraction
containing some
CD34 cells
Global LV function improved
in 4 and infarct tissue
perfusion improved in 5,
3-9 mo later
2-wk supraventricular
arrythmias
CABG a confounding
factor; specific role of
AC133 cells unknown
Tse 2003 [20] 8 Electromechanical
mapping guided by
percutaneous
catheter–mediated
transendocardial
injection in patients
with refractory stable
angina
BM mononuclear cells Improved regional wall
thickening and wall motion
and percentage of area of
hypoperfused myocardium
at 90 d
None Small pilot (no control
group)
Perin 2003 [21] 14 Transendocardial
delivery by catheter
and NOGA mapping in
patients with end-
stage ischemic heart
disease
BM mononuclear cells Improved global LV function
at 2 mo and improved EF
(20%-29%) and reduced
end-systolic volume at
4 mo
One patient died
suddenly at 14 wk
Results compared with 7
control patients
Fuchs 2003 [22] 10 Transendocardial
injection with
electromechanical
guidance in patients
with refractory severe
symptomatic chronic
myocardial ischemia
Filtered
unfractionated BM
cells.
Improvement in CCS angina
score and stress induced
ischemia but not treadmill
exercise duration at 3 mo
None (2 patients
readmitted for
pain)
Pilot study (no control
group)
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BB&Mf a lack, not only of hematopoietically derived cardi-
myocytes, but of the engraftment of hematopoietic
onor cells themselves [9], a re-evaluation is in order.
reclinical studies that correlate cardiac function end
oints with cell types and frequencies would be valu-
ble. Control experiments that evaluate potential
aracrine effects of the cells are also needed. Trans-
enic and xenogeneic animal models are available to
ddress these issues, and the results will allow us to
esign more pertinent clinical trials.
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